1. Volume 143, Issue 5, Pages e121S-e141S (May 2013)
Clinical and Organizational Factors in the Initial Evaluation of Patients With Lung Cancer 
David E. Ost, MD, MPH, FCCP, Sai-Ching Jim Yeung, MD, PhD, RPh, Lynn T. Tanoue, MD, FCCP, Michael K. Gould, MD, FCCP 
CHEST 
Volume 143, Issue 5, Pages e121S-e141S (May 2013)
DOI: /chest
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

2. Figure 1
[Introduction, Section 2.3] Overview of initial evaluation, diagnosis, staging, and treatment processes. There is significant overlap between cognitive processes. Developing a clinical diagnosis and assessment of the probable stage begins during the initial evaluation. This clinical assessment is subsequently refined on the basis of biopsy specimen findings that are part of formal staging and diagnosis. Similarly, information regarding the patient's functional status, comorbid conditions, and preferences may have an impact on treatment alternatives, and this in turn may have an impact on the type of diagnostic testing strategies chosen. CXR = chest radiograph.
CHEST  , e121S-e141SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

3. Figure 2
[Introduction] Diagnostic algorithm for patients with suspected non-small cell lung cancer. The initial evaluation provides information on comorbidities, functional status, preferences, and probable extent of disease. The results of the initial evaluation determine the optimal site and sequencing of additional diagnostic and staging tests. Staging and diagnosis will be most efficient if the most advanced site of disease is targeted first. *When there is overwhelming imaging evidence of distant metastases, biopsy of the most accessible site is sufficient. DLCO = diffusing capacity of lung for carbon monoxide; EBUS-NA = endobronchial ultrasound-guided needle aspiration.
CHEST  , e121S-e141SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

4. Figure 3
[Section 2.0] Range of frequencies of initial symptoms and signs of lung cancer.
CHEST  , e121S-e141SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

5. Figure 4
[Section 2.4.1] Features of a standardized evaluation for systemic metastases.
CHEST  , e121S-e141SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

6. Figure 5
[Section 3.0] Paraneoplastic syndromes in patients with lung cancer.
CHEST  , e121S-e141SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

7. Figure 6
[Section 3.1.4] Food and medications to avoid during urine collection for 5-HIAA measurement.
CHEST  , e121S-e141SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

8. Figure 7
[Section 3.2.1] Autoimmune paraneoplastic syndromes associated with lung cancer.
CHEST  , e121S-e141SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions

9. Figure 8
[Section 4.0] Time to treatment in US studies of timeliness of care in lung cancer.
CHEST  , e121S-e141SDOI: ( /chest )
Copyright © 2013 The American College of Chest Physicians Terms and Conditions